Please assess the completion status of the following clinical trial:

Trial Title: A 2 PART STUDY EVALUATING EDP-721 IN HEALTHY SUBJECTS AND EDP-721 IN COMBINATION WITH EDP-514 IN PATIENTS WITH CHRONIC HEPATITIS B VIRUS INFECTION.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
Part 1 (HV Population):~Inclusion Criteria:~* An informed consent document signed and dated by the subject.~* Healthy male and female subjects of any ethnic origin between the ages of 18 and 65 years, inclusive.~Exclusion Criteria:~* Clinically relevant evidence or history of illness or disease.~* Pregnant or nursing females.~* History of febrile illness within 7 days prior to the first dose of study drug or subjects with evidence of active infection.~* A positive urine drug screen at screening or Day -1.~* Current tobacco smokers or use of tobacco within 3 months prior to screening.~* Any condition possibly affecting drug absorption (e.g., gastrectomy, cholecystectomy).~* History of regular alcohol consumption.~* Receipt of any vaccine, an investigational agent or biological product within 28 days or 5 times the t½, whichever one is longer, prior to first dose.~Part 2 (CHB Population)~Inclusion Criteria (Nuc-Suppressed CHB Population)~* An informed consent document signed and dated by the subject.~* Healthy male and female subjects of any ethnic origin between the ages of 18 and 70 years, inclusive~* HBsAg detectable in serum/plasma at Screening and in the most recent HBsAg serum/plasma testing at least 6 months previously.~* HBV DNA levels:~  * A Screening HBV DNA level in serum/plasma that is \<LLOQ and~ * No HBV DNA serum/plasma test values ≥LLOQ over the previous 12 months (using an approved test)~* CHB subjects must have been on their prescribed HBV NUC treatment with no change in regimen for 12 months prior to Screening~Inclusion Criteria (Viremic CHB Population):~* An informed consent document signed and dated by the subject.~* Healthy male and female subjects of any ethnic origin between the ages of 18 and 70 years, inclusive~* HBsAg detectable in serum/plasma at Screening and in the most recent HBsAg serum/plasma testing at least 6 months previously.~* HBV DNA levels:~  * For subjects who are HBeAg positive at Screening, a Screening HBV DNA level in serum/plasma that is ≥20,000 IU/ml, or~ * For subjects who are HBeAg negative at Screening, a Screening HBV DNA level in serum/plasma that is ≥2,000 IU/mL, and~ * For all subjects, no HBV DNA serum/plasma test values \<1,000 IU/ml over the previous 12 months (using an approved test)~* CHB subjects must not have been on prescribed anti-HBV treatment, specifically pegIFN and/or NUC therapy for at least 12 months prior to Screening~Exclusion Criteria (Nuc-Suppressed and Viremic CHB Population):~* A documented prior diagnosis of cirrhosis~* Pregnant or nursing females~* Coinfection with human immunodeficiency virus (HIV), HCV, HDV, HAV, or HEV~* Chronic liver disease of a non-HBV etiology; coexisting liver or biliary diseases

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- EDP-721 HV SAD Cohorts (Type: EXPERIMENTAL): EDP-721 Dose 1, Dose 2, Dose 3 and Dose 4, in one single administration
- EDP-721 HV MAD Cohorts (Type: EXPERIMENTAL): EDP-721 Dose 1, Dose 2 and Dose 3, once daily for 14 days
- EDP-721 HV SAD Placebo Cohort (Type: PLACEBO_COMPARATOR): Matching placebo, in one single administration
- EDP-721 HV MAD Placebo Cohort (Type: PLACEBO_COMPARATOR): Matching placebo, once daily for 14 days
- EDP-721+ EDP-514 HBV MAD Cohorts (Type: EXPERIMENTAL): EDP-721 once daily for 14 days followed by EDP-721+EDP-514 once daily for 28 days
- EDP-721+ EDP-514 HBV MAD Placebo Cohorts (Type: PLACEBO_COMPARATOR): Matching placebo once daily for 42 days

Based on this trial design, predict the completion outcome and termination type (if applicable).